Results 331 to 340 of about 5,061,790 (379)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

The Role of Angiotensin-II Infusion in an Infant With Autosomal Recessive Polycystic Kidney Disease Postbilateral Nephrectomies and Refractory Hypotension in the Neonatal Period. [PDF]

Case Rep Nephrol
Nevarez Gilbert A, Rahde Bischoff A, Merrill K.   +2 more
europepmc   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Purinergic Receptor Activation Protects Glomerular Microvasculature from Increased Mechanical Stress in Angiotensin II-Induced Hypertension: A Modeling Study. [PDF]

Int J Mol Sci
Richfield O, Cortez R, Kulthinee S, Franco M, Navar LG.   +4 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source

Smooth muscle cells and fibroblasts in the ascending aorta exhibit minor differences between embryonic origins in angiotensin II-driven transcriptional alterations. [PDF]

Sci Rep
Ito S, Graf DB, Katsumata Y, Moorleghen JJ, Zhang C, Li Y, LeMaire SA, Shen YH, Lu HS, Daugherty A, Sawada H.   +10 more
europepmc   +1 more source

Predicting 1‐year heart failure hospitalization and mortality post‐discharge from the intensive cardiac care unit

ESC Heart Failure, EarlyView.
Abstract Aims Despite the high risk of rehospitalization for heart failure (HF) and death among patients admitted to the intensive cardiac care unit (ICCU), no accurate prediction score for these outcomes exists. We aimed to develop a risk score to predict unplanned HF hospitalization and death 1‐year post‐discharge in an unselected cohort of patients ...
Andreas Bugge Tinggaard, Solenn Toupin, Jean Guillaume Dillinger, Clément Delmas, Antonin Trimaille, Claire Bouleti, Guillaume Schurtz, Charles Fauvel, Jean Claude Dib, Stéphane Andrieu, François Roubille, Thomas Levasseur, Guillaume Bonnet, Marouane Boukhris, Thomas Bochaton, Vincent Roule, Laura Delsarte, Albert Boccara, Franck Albert, Franck Boccara, Etienne Puymirat, Henrik Wiggers, Alexandre Mebazaa, Alain Cohen‐Solal, Benjamin G. Chousterman, Patrick Henry, Théo Pezel, for the ADDICT‐ICCU Investigators, Victor Aboyans, Emeric Albert, Franck Albert, Sean Alvain, Nabil Amri, Stéphane Andrieu, Sabir Attou, Simon Auvray, Sonia Azzakani, Ruben Azencot, Marc Bedossa, Franck Boccara, Albert Boccara, Thomas Bochaton, Eric Bonnefoy‐Cudraz, Guillaume Bonnet, Nabil Bouali, Océane Bouchot, Claire Bouleti, Tanissia Boukertouta, Marouane Boukhris, Jean Baptiste Brette, Marjorie Canu, Aures Chaib, Clement Charbonnel, Anne Solene Chaussade, Alexandre Coppens, Yves Cottin, Arthur Darmon, Elena De Angelis, Clément Delmas, Laura Delsarte, Antoine Deney, Jean Claude Dib, Jean‐Guillaume Dillinger, Clemence Docq, Valentin Dupasquier, Meyer Elbaz, Antony El Hadad, Amine El Ouahidi, Nacim Ezzouhairi, Julien Fabre, Damien Fard, Charles Fauvel, Édouard Gerbaud, Martine Gilard, Marc Goralski, Nissim Grinberg, Alain Grentzinger, Marie Hauguel‐Moreau, Patrick Henry, Fabien Huet, Thomas Landemaine, Benoit Lattuca, Léo Lemarchand, Thomas Levasseur, Pascal Lim, Laura Maitre Ballesteros, Nicolas Mansencal, Benjamin Marie, David Martinez, Benoit Merat, Christophe Meune, Damien Millischer, Thomas Moine, Pascal Nhan, Nathalie Noirclerc, Patrick Ohlmann, Théo Pezel, Fabien Picard, Nicolas Piliero, Thibaut Pommier, Etienne Puymirat, Arthur Ramonatxo, Reza Rossanaly Vasram, François Roubille, Vincent Roule, Guillaume Schurtz, Mathilde Stevenard, David Sulman, Fédérico Swedsky, Victoria Tea, Eugénie Thevenet, Christophe Thuaire, Antonin Trimaille, Christophe Tron, Guillaume Viboud, Dominique Yomi, Cyril Zakine   +116 more
wiley   +1 more source

Angiotensin II administration in severe thrombocytopenia and chronic venous thrombosis: A case report.

World J Crit Care Med
Vujaklija Brajkovic A, Markota A, Bielen L, Vujević A, Rora M, Radonic R.   +5 more
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source